Industry Research Reports
Home > Reports > Consumer Goods > Pet Ectoparasiticide - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
Pet Ectoparasiticide - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
Industry: Consumer Goods
Published Date: 2025-11-10
Pages: 118 Pages
Report ld: 5432059
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Pet Ectoparasiticide Market Size(US$)
CAGR 2025-2031
6.0%
Market Size,2031
USD 2,379
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 1,674 million
Market Forecast in 2031(Value)
US$ 2,379 million
CAGR
6.0%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global market for Pet Ectoparasiticide was estimated to be worth US$ 1602 million in 2024 and is forecast to a readjusted size of US$ 2379 million by 2031 with a CAGR of 6.0% during the forecast period 2025-2031.
Pet ectoparasiticides are chemical or biological formulations designed to prevent, control, or eliminate external parasites such as fleas, ticks, mites, lice, and mosquitoes on companion animals like dogs and cats. These products work through contact or systemic action, disrupting parasite nerve function, reproduction, or metabolism. They are available in various dosage forms—topical solutions, oral tablets, sprays, shampoos, collars, and injectables—and play a key role in veterinary health for preventing zoonotic diseases, improving pet hygiene, and enhancing animal welfare.
The upstream segment includes suppliers of active pharmaceutical ingredients (APIs), excipients, emulsifiers, stabilizers, and packaging materials such as vials, sachets, and collars. The midstream segment encompasses pharmaceutical and veterinary companies that formulate, compound, and package ectoparasiticide products through chemical synthesis or biological extraction processes. Downstream segments consist of veterinary hospitals, clinics, distributors, and retailers that deliver products to pet owners. Supporting sectors include R&D laboratories developing novel compounds and regulatory authorities ensuring safety compliance under frameworks like EPA, EMA, and FDA. Data analytics and IoT-driven pet healthcare solutions are enhancing downstream marketing and treatment personalization.
Several veterinary pharmaceutical companies are expanding ectoparasiticide R&D and production facilities across the U.S., Europe, and Asia-Pacific. Projects include new pipeline developments in long-acting oral tablets and biodegradable flea collars. Emerging biotech startups are working on natural, plant-based, and nanoformulated ectoparasiticides for improved safety. Collaborative programs between academia and pharmaceutical firms are targeting resistance management and green synthesis technologies. Expansion plans in India and China focus on large-scale API production and global distribution to meet rising demand for pet care in developing urban markets.
2024 Global Market Average Gross Profit Margin: 42%.
North American market for Pet Ectoparasiticide was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Pet Ectoparasiticide was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Pet Ectoparasiticide was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global key companies of Pet Ectoparasiticide include Bayer, MSD Animal Health, Boehringer Ingelheim, Ceva Sante Animale, Elanco, Zoetis, Inc., Sanofi, Virbac, Vetoquinol S.A., Dechra Pharmaceuticals Plc, etc. In 2024, the global five largest players hold a share approximately % in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Pet Ectoparasiticide, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Pet Ectoparasiticide by region & country, by Type, and by Application.
The Pet Ectoparasiticide market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pet Ectoparasiticide.
MARKET SEGMENTATION
By Company
- Bayer
- MSD Animal Health
- Boehringer Ingelheim
- Ceva Sante Animale
- Elanco
- Zoetis, Inc.
- Sanofi
- Virbac
- Vetoquinol S.A.
- Dechra Pharmaceuticals Plc
- Advance Properties OOD/Huvepharma
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Spot-On Liquids
- Oral Chewable Tablets
- Sprays
- Collars
Segment by Application
- Dogs
- Cats
- Others
Segment by Category
- Fipronil-based
- Imidacloprid-based
- Permethrin-based
- Isoxazoline-class
Segment by Division
- Contact Ectoparasiticides
- Systemic Ectoparasiticides
- Natural/Biological Ectoparasiticides
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Pet Ectoparasiticide company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Pet Ectoparasiticide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Pet Ectoparasiticide in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Market Overview
1.1 Pet Ectoparasiticide Product Introduction
1.2 Global Pet Ectoparasiticide Market Size Forecast (2020-2031)
1.3 Pet Ectoparasiticide Market Trends & Drivers
1.3.1 Pet Ectoparasiticide Industry Trends
1.3.2 Pet Ectoparasiticide Market Drivers & Opportunity
1.3.3 Pet Ectoparasiticide Market Challenges
1.3.4 Pet Ectoparasiticide Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Pet Ectoparasiticide Players Revenue Ranking (2024)
2.2 Global Pet Ectoparasiticide Revenue by Company (2020-2025)
2.3 Key Companies Pet Ectoparasiticide Manufacturing Base Distribution and Headquarters
2.4 Key Companies Pet Ectoparasiticide Product Offered
2.5 Key Companies Time to Begin Mass Production of Pet Ectoparasiticide
2.6 Pet Ectoparasiticide Market Competitive Analysis
2.6.1 Pet Ectoparasiticide Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Pet Ectoparasiticide Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pet Ectoparasiticide as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Spot-On Liquids
3.1.2 Oral Chewable Tablets
3.1.3 Sprays
3.1.4 Collars
3.2 Global Pet Ectoparasiticide Sales Value by Type
3.2.1 Global Pet Ectoparasiticide Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Pet Ectoparasiticide Sales Value, by Type (2020-2031)
3.2.3 Global Pet Ectoparasiticide Sales Value, by Type (%) (2020-2031)
4 Segmentation by Active Ingredient
4.1 Introduction by Active Ingredient
4.1.1 Fipronil-based
4.1.2 Imidacloprid-based
4.1.3 Permethrin-based
4.1.4 Isoxazoline-class
4.2 Global Pet Ectoparasiticide Sales Value by Active Ingredient
4.2.1 Global Pet Ectoparasiticide Sales Value by Active Ingredient (2020 VS 2024 VS 2031)
4.2.2 Global Pet Ectoparasiticide Sales Value, by Active Ingredient (2020-2031)
4.2.3 Global Pet Ectoparasiticide Sales Value, by Active Ingredient (%) (2020-2031)
5 Segmentation by Mode of Action
5.1 Introduction by Mode of Action
5.1.1 Contact Ectoparasiticides
5.1.2 Systemic Ectoparasiticides
5.1.3 Natural/Biological Ectoparasiticides
5.2 Global Pet Ectoparasiticide Sales Value by Mode of Action
5.2.1 Global Pet Ectoparasiticide Sales Value by Mode of Action (2020 VS 2024 VS 2031)
5.2.2 Global Pet Ectoparasiticide Sales Value, by Mode of Action (2020-2031)
5.2.3 Global Pet Ectoparasiticide Sales Value, by Mode of Action (%) (2020-2031)
6 Segmentation by Distribution Channel
6.1 Introduction by Distribution Channel
6.1.1 Veterinary Clinics
6.1.2 Pet Specialty Stores
6.1.3 Online Retail/E-Commerce
6.1.4 Pharmacy Chains
6.2 Global Pet Ectoparasiticide Sales Value by Distribution Channel
6.2.1 Global Pet Ectoparasiticide Sales Value by Distribution Channel (2020 VS 2024 VS 2031)
6.2.2 Global Pet Ectoparasiticide Sales Value, by Distribution Channel (2020-2031)
6.2.3 Global Pet Ectoparasiticide Sales Value, by Distribution Channel (%) (2020-2031)
7 Segmentation by Application
7.1 Introduction by Application
7.1.1 Dogs
7.1.2 Cats
7.1.3 Others
7.2 Global Pet Ectoparasiticide Sales Value by Application
7.2.1 Global Pet Ectoparasiticide Sales Value by Application (2020 VS 2024 VS 2031)
7.2.2 Global Pet Ectoparasiticide Sales Value, by Application (2020-2031)
7.2.3 Global Pet Ectoparasiticide Sales Value, by Application (%) (2020-2031)
8 Segmentation by Region
8.1 Global Pet Ectoparasiticide Sales Value by Region
8.1.1 Global Pet Ectoparasiticide Sales Value by Region: 2020 VS 2024 VS 2031
8.1.2 Global Pet Ectoparasiticide Sales Value by Region (2020-2025)
8.1.3 Global Pet Ectoparasiticide Sales Value by Region (2026-2031)
8.1.4 Global Pet Ectoparasiticide Sales Value by Region (%), (2020-2031)
8.2 North America
8.2.1 North America Pet Ectoparasiticide Sales Value, 2020-2031
8.2.2 North America Pet Ectoparasiticide Sales Value by Country (%), 2024 VS 2031
8.3 Europe
8.3.1 Europe Pet Ectoparasiticide Sales Value, 2020-2031
8.3.2 Europe Pet Ectoparasiticide Sales Value by Country (%), 2024 VS 2031
8.4 Asia Pacific
8.4.1 Asia Pacific Pet Ectoparasiticide Sales Value, 2020-2031
8.4.2 Asia Pacific Pet Ectoparasiticide Sales Value by Region (%), 2024 VS 2031
8.5 South America
8.5.1 South America Pet Ectoparasiticide Sales Value, 2020-2031
8.5.2 South America Pet Ectoparasiticide Sales Value by Country (%), 2024 VS 2031
8.6 Middle East & Africa
8.6.1 Middle East & Africa Pet Ectoparasiticide Sales Value, 2020-2031
8.6.2 Middle East & Africa Pet Ectoparasiticide Sales Value by Country (%), 2024 VS 2031
9 Segmentation by Key Countries/Regions
9.1 Key Countries/Regions Pet Ectoparasiticide Sales Value Growth Trends, 2020 VS 2024 VS 2031
9.2 Key Countries/Regions Pet Ectoparasiticide Sales Value, 2020-2031
9.3 United States
9.3.1 United States Pet Ectoparasiticide Sales Value, 2020-2031
9.3.2 United States Pet Ectoparasiticide Sales Value by Type (%), 2024 VS 2031
9.3.3 United States Pet Ectoparasiticide Sales Value by Application, 2024 VS 2031
9.4 Europe
9.4.1 Europe Pet Ectoparasiticide Sales Value, 2020-2031
9.4.2 Europe Pet Ectoparasiticide Sales Value by Type (%), 2024 VS 2031
9.4.3 Europe Pet Ectoparasiticide Sales Value by Application, 2024 VS 2031
9.5 China
9.5.1 China Pet Ectoparasiticide Sales Value, 2020-2031
9.5.2 China Pet Ectoparasiticide Sales Value by Type (%), 2024 VS 2031
9.5.3 China Pet Ectoparasiticide Sales Value by Application, 2024 VS 2031
9.6 Japan
9.6.1 Japan Pet Ectoparasiticide Sales Value, 2020-2031
9.6.2 Japan Pet Ectoparasiticide Sales Value by Type (%), 2024 VS 2031
9.6.3 Japan Pet Ectoparasiticide Sales Value by Application, 2024 VS 2031
9.7 South Korea
9.7.1 South Korea Pet Ectoparasiticide Sales Value, 2020-2031
9.7.2 South Korea Pet Ectoparasiticide Sales Value by Type (%), 2024 VS 2031
9.7.3 South Korea Pet Ectoparasiticide Sales Value by Application, 2024 VS 2031
9.8 Southeast Asia
9.8.1 Southeast Asia Pet Ectoparasiticide Sales Value, 2020-2031
9.8.2 Southeast Asia Pet Ectoparasiticide Sales Value by Type (%), 2024 VS 2031
9.8.3 Southeast Asia Pet Ectoparasiticide Sales Value by Application, 2024 VS 2031
9.9 India
9.9.1 India Pet Ectoparasiticide Sales Value, 2020-2031
9.9.2 India Pet Ectoparasiticide Sales Value by Type (%), 2024 VS 2031
9.9.3 India Pet Ectoparasiticide Sales Value by Application, 2024 VS 2031
10 Company Profiles
10.1 Bayer
10.1.1 Bayer Profile
10.1.2 Bayer Main Business
10.1.3 Bayer Pet Ectoparasiticide Products, Services and Solutions
10.1.4 Bayer Pet Ectoparasiticide Revenue (US$ Million) & (2020-2025)
10.1.5 Bayer Recent Developments
10.2 MSD Animal Health
10.2.1 MSD Animal Health Profile
10.2.2 MSD Animal Health Main Business
10.2.3 MSD Animal Health Pet Ectoparasiticide Products, Services and Solutions
10.2.4 MSD Animal Health Pet Ectoparasiticide Revenue (US$ Million) & (2020-2025)
10.2.5 MSD Animal Health Recent Developments
10.3 Boehringer Ingelheim
10.3.1 Boehringer Ingelheim Profile
10.3.2 Boehringer Ingelheim Main Business
10.3.3 Boehringer Ingelheim Pet Ectoparasiticide Products, Services and Solutions
10.3.4 Boehringer Ingelheim Pet Ectoparasiticide Revenue (US$ Million) & (2020-2025)
10.3.5 Boehringer Ingelheim Recent Developments
10.4 Ceva Sante Animale
10.4.1 Ceva Sante Animale Profile
10.4.2 Ceva Sante Animale Main Business
10.4.3 Ceva Sante Animale Pet Ectoparasiticide Products, Services and Solutions
10.4.4 Ceva Sante Animale Pet Ectoparasiticide Revenue (US$ Million) & (2020-2025)
10.4.5 Ceva Sante Animale Recent Developments
10.5 Elanco
10.5.1 Elanco Profile
10.5.2 Elanco Main Business
10.5.3 Elanco Pet Ectoparasiticide Products, Services and Solutions
10.5.4 Elanco Pet Ectoparasiticide Revenue (US$ Million) & (2020-2025)
10.5.5 Elanco Recent Developments
10.6 Zoetis, Inc.
10.6.1 Zoetis, Inc. Profile
10.6.2 Zoetis, Inc. Main Business
10.6.3 Zoetis, Inc. Pet Ectoparasiticide Products, Services and Solutions
10.6.4 Zoetis, Inc. Pet Ectoparasiticide Revenue (US$ Million) & (2020-2025)
10.6.5 Zoetis, Inc. Recent Developments
10.7 Sanofi
10.7.1 Sanofi Profile
10.7.2 Sanofi Main Business
10.7.3 Sanofi Pet Ectoparasiticide Products, Services and Solutions
10.7.4 Sanofi Pet Ectoparasiticide Revenue (US$ Million) & (2020-2025)
10.7.5 Sanofi Recent Developments
10.8 Virbac
10.8.1 Virbac Profile
10.8.2 Virbac Main Business
10.8.3 Virbac Pet Ectoparasiticide Products, Services and Solutions
10.8.4 Virbac Pet Ectoparasiticide Revenue (US$ Million) & (2020-2025)
10.8.5 Virbac Recent Developments
10.9 Vetoquinol S.A.
10.9.1 Vetoquinol S.A. Profile
10.9.2 Vetoquinol S.A. Main Business
10.9.3 Vetoquinol S.A. Pet Ectoparasiticide Products, Services and Solutions
10.9.4 Vetoquinol S.A. Pet Ectoparasiticide Revenue (US$ Million) & (2020-2025)
10.9.5 Vetoquinol S.A. Recent Developments
10.10 Dechra Pharmaceuticals Plc
10.10.1 Dechra Pharmaceuticals Plc Profile
10.10.2 Dechra Pharmaceuticals Plc Main Business
10.10.3 Dechra Pharmaceuticals Plc Pet Ectoparasiticide Products, Services and Solutions
10.10.4 Dechra Pharmaceuticals Plc Pet Ectoparasiticide Revenue (US$ Million) & (2020-2025)
10.10.5 Dechra Pharmaceuticals Plc Recent Developments
10.11 Advance Properties OOD/Huvepharma
10.11.1 Advance Properties OOD/Huvepharma Profile
10.11.2 Advance Properties OOD/Huvepharma Main Business
10.11.3 Advance Properties OOD/Huvepharma Pet Ectoparasiticide Products, Services and Solutions
10.11.4 Advance Properties OOD/Huvepharma Pet Ectoparasiticide Revenue (US$ Million) & (2020-2025)
10.11.5 Advance Properties OOD/Huvepharma Recent Developments
11 Industry Chain Analysis
11.1 Pet Ectoparasiticide Industrial Chain
11.2 Pet Ectoparasiticide Upstream Analysis
11.2.1 Key Raw Materials
11.2.2 Raw Materials Key Suppliers
11.2.3 Manufacturing Cost Structure
11.3 Midstream Analysis
11.4 Downstream Analysis (Customers Analysis)
11.5 Sales Model and Sales Channels
11.5.1 Pet Ectoparasiticide Sales Model
11.5.2 Sales Channel
11.5.3 Pet Ectoparasiticide Distributors
12 Research Findings and Conclusion
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Pet Ectoparasiticide Market Trends
Table 2. Pet Ectoparasiticide Market Drivers & Opportunity
Table 3. Pet Ectoparasiticide Market Challenges
Table 4. Pet Ectoparasiticide Market Restraints
Table 5. Global Pet Ectoparasiticide Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global Pet Ectoparasiticide Revenue Market Share by Company (2020-2025)
Table 7. Key Companies Pet Ectoparasiticide Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Pet Ectoparasiticide Product Type
Table 9. Key Companies Time to Begin Mass Production of Pet Ectoparasiticide
Table 10. Global Pet Ectoparasiticide Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pet Ectoparasiticide as of 2024)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Pet Ectoparasiticide Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 14. Global Pet Ectoparasiticide Sales Value by Type (2020-2025) & (US$ Million)
Table 15. Global Pet Ectoparasiticide Sales Value by Type (2026-2031) & (US$ Million)
Table 16. Global Pet Ectoparasiticide Sales Market Share in Value by Type (2020-2025)
Table 17. Global Pet Ectoparasiticide Sales Market Share in Value by Type (2026-2031)
Table 18. Global Pet Ectoparasiticide Sales Value by Active Ingredient: 2020 VS 2024 VS 2031 (US$ Million)
Table 19. Global Pet Ectoparasiticide Sales Value by Active Ingredient (2020-2025) & (US$ Million)
Table 20. Global Pet Ectoparasiticide Sales Value by Active Ingredient (2026-2031) & (US$ Million)
Table 21. Global Pet Ectoparasiticide Sales Market Share in Value by Active Ingredient (2020-2025)
Table 22. Global Pet Ectoparasiticide Sales Market Share in Value by Active Ingredient (2026-2031)
Table 23. Global Pet Ectoparasiticide Sales Value by Mode of Action: 2020 VS 2024 VS 2031 (US$ Million)
Table 24. Global Pet Ectoparasiticide Sales Value by Mode of Action (2020-2025) & (US$ Million)
Table 25. Global Pet Ectoparasiticide Sales Value by Mode of Action (2026-2031) & (US$ Million)
Table 26. Global Pet Ectoparasiticide Sales Market Share in Value by Mode of Action (2020-2025)
Table 27. Global Pet Ectoparasiticide Sales Market Share in Value by Mode of Action (2026-2031)
Table 28. Global Pet Ectoparasiticide Sales Value by Distribution Channel: 2020 VS 2024 VS 2031 (US$ Million)
Table 29. Global Pet Ectoparasiticide Sales Value by Distribution Channel (2020-2025) & (US$ Million)
Table 30. Global Pet Ectoparasiticide Sales Value by Distribution Channel (2026-2031) & (US$ Million)
Table 31. Global Pet Ectoparasiticide Sales Market Share in Value by Distribution Channel (2020-2025)
Table 32. Global Pet Ectoparasiticide Sales Market Share in Value by Distribution Channel (2026-2031)
Table 33. Global Pet Ectoparasiticide Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 34. Global Pet Ectoparasiticide Sales Value by Application (2020-2025) & (US$ Million)
Table 35. Global Pet Ectoparasiticide Sales Value by Application (2026-2031) & (US$ Million)
Table 36. Global Pet Ectoparasiticide Sales Market Share in Value by Application (2020-2025)
Table 37. Global Pet Ectoparasiticide Sales Market Share in Value by Application (2026-2031)
Table 38. Global Pet Ectoparasiticide Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 39. Global Pet Ectoparasiticide Sales Value by Region (2020-2025) & (US$ Million)
Table 40. Global Pet Ectoparasiticide Sales Value by Region (2026-2031) & (US$ Million)
Table 41. Global Pet Ectoparasiticide Sales Value by Region (2020-2025) & (%)
Table 42. Global Pet Ectoparasiticide Sales Value by Region (2026-2031) & (%)
Table 43. Key Countries/Regions Pet Ectoparasiticide Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 44. Key Countries/Regions Pet Ectoparasiticide Sales Value, (2020-2025) & (US$ Million)
Table 45. Key Countries/Regions Pet Ectoparasiticide Sales Value, (2026-2031) & (US$ Million)
Table 46. Bayer Basic Information List
Table 47. Bayer Description and Business Overview
Table 48. Bayer Pet Ectoparasiticide Products, Services and Solutions
Table 49. Revenue (US$ Million) in Pet Ectoparasiticide Business of Bayer (2020-2025)
Table 50. Bayer Recent Developments
Table 51. MSD Animal Health Basic Information List
Table 52. MSD Animal Health Description and Business Overview
Table 53. MSD Animal Health Pet Ectoparasiticide Products, Services and Solutions
Table 54. Revenue (US$ Million) in Pet Ectoparasiticide Business of MSD Animal Health (2020-2025)
Table 55. MSD Animal Health Recent Developments
Table 56. Boehringer Ingelheim Basic Information List
Table 57. Boehringer Ingelheim Description and Business Overview
Table 58. Boehringer Ingelheim Pet Ectoparasiticide Products, Services and Solutions
Table 59. Revenue (US$ Million) in Pet Ectoparasiticide Business of Boehringer Ingelheim (2020-2025)
Table 60. Boehringer Ingelheim Recent Developments
Table 61. Ceva Sante Animale Basic Information List
Table 62. Ceva Sante Animale Description and Business Overview
Table 63. Ceva Sante Animale Pet Ectoparasiticide Products, Services and Solutions
Table 64. Revenue (US$ Million) in Pet Ectoparasiticide Business of Ceva Sante Animale (2020-2025)
Table 65. Ceva Sante Animale Recent Developments
Table 66. Elanco Basic Information List
Table 67. Elanco Description and Business Overview
Table 68. Elanco Pet Ectoparasiticide Products, Services and Solutions
Table 69. Revenue (US$ Million) in Pet Ectoparasiticide Business of Elanco (2020-2025)
Table 70. Elanco Recent Developments
Table 71. Zoetis, Inc. Basic Information List
Table 72. Zoetis, Inc. Description and Business Overview
Table 73. Zoetis, Inc. Pet Ectoparasiticide Products, Services and Solutions
Table 74. Revenue (US$ Million) in Pet Ectoparasiticide Business of Zoetis, Inc. (2020-2025)
Table 75. Zoetis, Inc. Recent Developments
Table 76. Sanofi Basic Information List
Table 77. Sanofi Description and Business Overview
Table 78. Sanofi Pet Ectoparasiticide Products, Services and Solutions
Table 79. Revenue (US$ Million) in Pet Ectoparasiticide Business of Sanofi (2020-2025)
Table 80. Sanofi Recent Developments
Table 81. Virbac Basic Information List
Table 82. Virbac Description and Business Overview
Table 83. Virbac Pet Ectoparasiticide Products, Services and Solutions
Table 84. Revenue (US$ Million) in Pet Ectoparasiticide Business of Virbac (2020-2025)
Table 85. Virbac Recent Developments
Table 86. Vetoquinol S.A. Basic Information List
Table 87. Vetoquinol S.A. Description and Business Overview
Table 88. Vetoquinol S.A. Pet Ectoparasiticide Products, Services and Solutions
Table 89. Revenue (US$ Million) in Pet Ectoparasiticide Business of Vetoquinol S.A. (2020-2025)
Table 90. Vetoquinol S.A. Recent Developments
Table 91. Dechra Pharmaceuticals Plc Basic Information List
Table 92. Dechra Pharmaceuticals Plc Description and Business Overview
Table 93. Dechra Pharmaceuticals Plc Pet Ectoparasiticide Products, Services and Solutions
Table 94. Revenue (US$ Million) in Pet Ectoparasiticide Business of Dechra Pharmaceuticals Plc (2020-2025)
Table 95. Dechra Pharmaceuticals Plc Recent Developments
Table 96. Advance Properties OOD/Huvepharma Basic Information List
Table 97. Advance Properties OOD/Huvepharma Description and Business Overview
Table 98. Advance Properties OOD/Huvepharma Pet Ectoparasiticide Products, Services and Solutions
Table 99. Revenue (US$ Million) in Pet Ectoparasiticide Business of Advance Properties OOD/Huvepharma (2020-2025)
Table 100. Advance Properties OOD/Huvepharma Recent Developments
Table 101. Key Raw Materials Lists
Table 102. Raw Materials Key Suppliers Lists
Table 103. Pet Ectoparasiticide Downstream Customers
Table 104. Pet Ectoparasiticide Distributors List
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
List of Figures
Figure 1. Pet Ectoparasiticide Product Picture
Figure 2. Global Pet Ectoparasiticide Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Pet Ectoparasiticide Sales Value (2020-2031) & (US$ Million)
Figure 4. Pet Ectoparasiticide Report Years Considered
Figure 5. Global Pet Ectoparasiticide Players Revenue Ranking (2024) & (US$ Million)
Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Pet Ectoparasiticide Revenue in 2024
Figure 7. Pet Ectoparasiticide Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 8. Spot-On Liquids Picture
Figure 9. Oral Chewable Tablets Picture
Figure 10. Sprays Picture
Figure 11. Collars Picture
Figure 12. Global Pet Ectoparasiticide Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 13. Global Pet Ectoparasiticide Sales Value Market Share by Type, 2024 & 2031
Figure 14. Fipronil-based Picture
Figure 15. Imidacloprid-based Picture
Figure 16. Permethrin-based Picture
Figure 17. Isoxazoline-class Picture
Figure 18. Global Pet Ectoparasiticide Sales Value by Active Ingredient (2020 VS 2024 VS 2031) & (US$ Million)
Figure 19. Global Pet Ectoparasiticide Sales Value Market Share by Active Ingredient, 2024 & 2031
Figure 20. Contact Ectoparasiticides Picture
Figure 21. Systemic Ectoparasiticides Picture
Figure 22. Natural/Biological Ectoparasiticides Picture
Figure 23. Global Pet Ectoparasiticide Sales Value by Mode of Action (2020 VS 2024 VS 2031) & (US$ Million)
Figure 24. Global Pet Ectoparasiticide Sales Value Market Share by Mode of Action, 2024 & 2031
Figure 25. Veterinary Clinics Picture
Figure 26. Pet Specialty Stores Picture
Figure 27. Online Retail/E-Commerce Picture
Figure 28. Pharmacy Chains Picture
Figure 29. Global Pet Ectoparasiticide Sales Value by Distribution Channel (2020 VS 2024 VS 2031) & (US$ Million)
Figure 30. Global Pet Ectoparasiticide Sales Value Market Share by Distribution Channel, 2024 & 2031
Figure 31. Product Picture of Dogs
Figure 32. Product Picture of Cats
Figure 33. Product Picture of Others
Figure 34. Global Pet Ectoparasiticide Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 35. Global Pet Ectoparasiticide Sales Value Market Share by Application, 2024 & 2031
Figure 36. North America Pet Ectoparasiticide Sales Value (2020-2031) & (US$ Million)
Figure 37. North America Pet Ectoparasiticide Sales Value by Country (%), 2024 VS 2031
Figure 38. Europe Pet Ectoparasiticide Sales Value, (2020-2031) & (US$ Million)
Figure 39. Europe Pet Ectoparasiticide Sales Value by Country (%), 2024 VS 2031
Figure 40. Asia Pacific Pet Ectoparasiticide Sales Value, (2020-2031) & (US$ Million)
Figure 41. Asia Pacific Pet Ectoparasiticide Sales Value by Region (%), 2024 VS 2031
Figure 42. South America Pet Ectoparasiticide Sales Value, (2020-2031) & (US$ Million)
Figure 43. South America Pet Ectoparasiticide Sales Value by Country (%), 2024 VS 2031
Figure 44. Middle East & Africa Pet Ectoparasiticide Sales Value, (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Pet Ectoparasiticide Sales Value by Country (%), 2024 VS 2031
Figure 46. Key Countries/Regions Pet Ectoparasiticide Sales Value (%), (2020-2031)
Figure 47. United States Pet Ectoparasiticide Sales Value, (2020-2031) & (US$ Million)
Figure 48. United States Pet Ectoparasiticide Sales Value by Type (%), 2024 VS 2031
Figure 49. United States Pet Ectoparasiticide Sales Value by Application (%), 2024 VS 2031
Figure 50. Europe Pet Ectoparasiticide Sales Value, (2020-2031) & (US$ Million)
Figure 51. Europe Pet Ectoparasiticide Sales Value by Type (%), 2024 VS 2031
Figure 52. Europe Pet Ectoparasiticide Sales Value by Application (%), 2024 VS 2031
Figure 53. China Pet Ectoparasiticide Sales Value, (2020-2031) & (US$ Million)
Figure 54. China Pet Ectoparasiticide Sales Value by Type (%), 2024 VS 2031
Figure 55. China Pet Ectoparasiticide Sales Value by Application (%), 2024 VS 2031
Figure 56. Japan Pet Ectoparasiticide Sales Value, (2020-2031) & (US$ Million)
Figure 57. Japan Pet Ectoparasiticide Sales Value by Type (%), 2024 VS 2031
Figure 58. Japan Pet Ectoparasiticide Sales Value by Application (%), 2024 VS 2031
Figure 59. South Korea Pet Ectoparasiticide Sales Value, (2020-2031) & (US$ Million)
Figure 60. South Korea Pet Ectoparasiticide Sales Value by Type (%), 2024 VS 2031
Figure 61. South Korea Pet Ectoparasiticide Sales Value by Application (%), 2024 VS 2031
Figure 62. Southeast Asia Pet Ectoparasiticide Sales Value, (2020-2031) & (US$ Million)
Figure 63. Southeast Asia Pet Ectoparasiticide Sales Value by Type (%), 2024 VS 2031
Figure 64. Southeast Asia Pet Ectoparasiticide Sales Value by Application (%), 2024 VS 2031
Figure 65. India Pet Ectoparasiticide Sales Value, (2020-2031) & (US$ Million)
Figure 66. India Pet Ectoparasiticide Sales Value by Type (%), 2024 VS 2031
Figure 67. India Pet Ectoparasiticide Sales Value by Application (%), 2024 VS 2031
Figure 68. Pet Ectoparasiticide Industrial Chain
Figure 69. Pet Ectoparasiticide Manufacturing Cost Structure
Figure 70. Channels of Distribution (Direct Sales, and Distribution)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What was the global market size of Pet Ectoparasiticide in 2031?
The global market size of Pet Ectoparasiticide in 2031 was 2379 Million USD.
Which region is expected to have the highest market share?
Which companies rank high in the global Pet Ectoparasiticide market?
What is the annual compound growth rate of the global Pet Ectoparasiticide market size from 2025 to 2031?
What was the global market size of Pet Ectoparasiticide in 2025?
Related Reports
Global Pet Ectoparasiticide Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Pet Ectoparasiticide market is projected to grow from US$ 1674 million in 2025 to US$ 2508 million by 2032, at a CAGR of 6.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-10
Pages: 144
USD 4900.00
(Single User License)
Global Pet Ectoparasiticide Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Pet Ectoparasiticide market size was US$ 1674 million in 2025 and is forecast to reach a readjusted size of US$ 2508 million by 2032 with a CAGR of 6.0% during the forecast period 2026-2032.
Published Date: 2026-03-10
Pages: 93
USD 4250.00
(Single User License)
Global Pet Ectoparasiticide Market Research Report 2026
The global Pet Ectoparasiticide market was valued at US$ 1674 million in 2025 and is anticipated to reach US$ 2508 million by 2032, at a CAGR of 6.0% from 2026 to 2032.
Published Date: 2026-03-10
Pages: 118
USD 2900.00
(Single User License)
Pet Ectoparasiticide - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Pet Ectoparasiticide was estimated to be worth US$ 1674 million in 2025 and is projected to reach US$ 2508 million, growing at a CAGR of 6.0% from 2026 to 2032.
Published Date: 2026-03-10
Pages: 107
USD 3950.00
(Single User License)
Global Pet Ectoparasiticide Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Pet Ectoparasiticide market is projected to grow from US$ 1602 million in 2024 to US$ 2379 million by 2031, at a CAGR of 6.0% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-11-10
Pages: 134
USD 4900.00
(Single User License)
Global Pet Ectoparasiticide Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Pet Ectoparasiticide market size was US$ 1602 million in 2024 and is forecast to a readjusted size of US$ 2379 million by 2031 with a CAGR of 6.0% during the forecast period 2025-2031.
Published Date: 2025-11-10
Pages: 93
USD 4250.00
(Single User License)
Global Pet Ectoparasiticide Market Research Report 2025
The global market for Pet Ectoparasiticide was valued at US$ 1602 million in the year 2024 and is projected to reach a revised size of US$ 2379 million by 2031, growing at a CAGR of 6.0% during the forecast period.
Published Date: 2025-11-10
Pages: 88
USD 2900.00
(Single User License)
Global Pet Ectoparasiticide Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Pet Ectoparasiticide market is projected to grow from US$ 1674 million in 2025 to US$ 2508 million by 2032, at a CAGR of 6.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-10
Pages: 144
USD 4900.00 (Single User License)Global Pet Ectoparasiticide Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Pet Ectoparasiticide market size was US$ 1674 million in 2025 and is forecast to reach a readjusted size of US$ 2508 million by 2032 with a CAGR of 6.0% during the forecast period 2026-2032.
Published: 2026-03-10
Pages: 93
USD 4250.00 (Single User License)Global Pet Ectoparasiticide Market Research Report 2026
The global Pet Ectoparasiticide market was valued at US$ 1674 million in 2025 and is anticipated to reach US$ 2508 million by 2032, at a CAGR of 6.0% from 2026 to 2032.
Published: 2026-03-10
Pages: 118
USD 2900.00 (Single User License)Pet Ectoparasiticide - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Pet Ectoparasiticide was estimated to be worth US$ 1674 million in 2025 and is projected to reach US$ 2508 million, growing at a CAGR of 6.0% from 2026 to 2032.
Published: 2026-03-10
Pages: 107
USD 3950.00 (Single User License)Global Pet Ectoparasiticide Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Pet Ectoparasiticide market is projected to grow from US$ 1602 million in 2024 to US$ 2379 million by 2031, at a CAGR of 6.0% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-11-10
Pages: 134
USD 4900.00 (Single User License)Global Pet Ectoparasiticide Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Pet Ectoparasiticide market size was US$ 1602 million in 2024 and is forecast to a readjusted size of US$ 2379 million by 2031 with a CAGR of 6.0% during the forecast period 2025-2031.
Published: 2025-11-10
Pages: 93
USD 4250.00 (Single User License)Global Pet Ectoparasiticide Market Research Report 2025
The global market for Pet Ectoparasiticide was valued at US$ 1602 million in the year 2024 and is projected to reach a revised size of US$ 2379 million by 2031, growing at a CAGR of 6.0% during the forecast period.
Published: 2025-11-10
Pages: 88
USD 2900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 3950.00
USD 5925.00
USD 7900.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now